Completed PHASE1 INTERVENTIONAL 6-arm NCT04523571

Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects

Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects: A Phase I, Randomized, Placebo-controlled, Observer-blind Study

Sponsor: BioNTech SE

Conditions SARS-CoV-2

Interventions BNT162b1 Placebo

Updated 9 times since 2020 Last updated: Sep 15, 2023 Started: Jul 28, 2020 Primary completion: Sep 30, 2020 Completion: Aug 10, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates SARS-CoV-2 and is currently completed. BioNTech SE leads this study, which shows 9 recorded versions since 2020 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Oct 2023 — Jul 2024 [monthly]

Completed PHASE1
May 2022 — Oct 2023 [monthly]

Completed PHASE1
Dec 2021 — May 2022 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed

▶ Show 4 earlier versions

Jan 2021 — Dec 2021 [monthly]

Active Not Recruiting PHASE1
Dec 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Nov 2020 — Dec 2020 [monthly]

Recruiting PHASE1
Sep 2020 — Nov 2020 [monthly]

Recruiting PHASE1

First recorded

Jul 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

BioNTech SE
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Data source: BioNTech SE

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Taizhou, China